Biologic therapies and pregnancy: The story so far

Rheumatology (United Kingdom)

Volumn 53, Issue 8, 2014, Pages 1377-1385

  Hyrich, Kimme L ^a   Verstappen, Suzanne M M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Abatacept; Anakinra; Anti TNF therapies; Biologic therapies; Breastfeeding; Inflammatory arthritis; Pregnancy outcomes; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; LIVE VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; BREAST FEEDING; CHILD DEVELOPMENT; CLUBFOOT; CONCEPTION; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DRUG SAFETY; ESOPHAGUS ATRESIA; FATHER; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATORY BOWEL DISEASE; LIVE BIRTH; MATERNAL MORTALITY; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMATIC REVIEW (TOPIC); THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME;

ABATACEPT; ANAKINRA; ANTI-TNF THERAPIES; BIOLOGIC THERAPIES; BREASTFEEDING; INFLAMMATORY ARTHRITIS; PREGNANCY OUTCOMES; RITUXIMAB; TOCILIZUMAB;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84904913086     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket409     Document Type: Review

References (66)

1. Electronic Medicines Compendium. http://www.medicines.org.uk/emc/(17 July 2013, date last accessed).
2. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
3. Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the timedependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
4. Davies R, Dixon WG, Watson KD et al. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann Rheum Dis 2013;72:461-2.
5. Dixon WG, Watson K, Lunt M et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376.
6. Posfay-Barbe KM, Wald ER. Listeriosis. Semin Fetal Neonatal Med 2009;14:228-233.
7. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003;21:3365-9.
8. Palmeira P, Quinello C, Silveira-Lessa AL et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012;2012:985646.
9. Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis 2013;26:248-53.
10. Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92.
11. Wakefield I, Stephens S, Foulkes R et al. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab0 monoclonal antibody. Toxicol Sci 2011;122:170-6.
12. Verstappen SM, King Y, Watson KD et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823-6.
13. Vinet E, Pineau C, Gordon C et al. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61:587-92.
14. Marchioni RM, Lichtenstein GR. Tumor necrosis factoralpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013;19:2591-602.
15. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013;108:1426-38.
16. Ali YM, Kuriya B, Orozco C et al. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9-17.
17. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008;57:1-5.
18. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factoralpha inhibition and VATER association: a causal relationship. J Rheumatol 2006;33:1014-7.
19. Carter JD, Ladhani A, Ricca LR et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
20. Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009;36:465-6.
21. Winger EE, Reed JL. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy? J Rheumatol 2009;36. 2122.
22. Clowse M, Wolf DC, Stach C et al. Outcomes of pregnancy in subjects exposed to certolizumab pegol [abstract 1643]. Arthritis Rheum 2012;64(Suppl):S702.
23. Martin PL, Oneda S, Treacy G. Effects of an anti-TNFalpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 2007;58:138-49.
24. Zelinkova Z, de Haar C, de Ridder L et al. High intrauterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053-8.
25. Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
26. Cheent K, Nolan J, Shariq S et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5.
27. Chakravarty EF, Murray ER, Kelman A et al. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117:1499-506.
28. Sangle SR, Lutalo PM, Davies RJ et al. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun 2013;43:55-9.
29. Klink DT, van Elburg RM, Schreurs MW et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008;2008:271363.
30. Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol 2011;29:1021-3.
31. Berger CT, Recher M, Steiner U et al. A patient's wish: anakinra in pregnancy. Ann Rheum Dis 2009;68:1794-5.
32. Ojeda-Uribe M, Afif N, Dahan E et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013;32:695-700.
33. Rubbert-Roth A, Goupille P, Moosavi S et al. First experiences with pregnancies in RA patients receiving tocilizumab therapy. Arthritis Rheum 2010;62:S161.
34. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am 2013;60:49-74.
35. Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients 2011;3:442-74.
36. Montagna GL, Malesci D, Buono R et al. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. Ann Rheum Dis 2005;64:1667.
37. Mahadevan U, Terdiman JP, Aron J et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:395-9.
38. Villiger PM, Caliezi G, Cottin V et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010;69:1842-4.
39. Saougou I, Markatseli TE, Papagoras C et al. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine 2013;80:34-7.
40. Katz JA, Antoni C, Keenan GE et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
41. Fritzsche J, Pilch A, Mury D et al. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol 2012;46:718-9.
42. Ben-Horin S, Yavzori M, Katz L et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010;8:475-6.
43. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004;31:1017-8.
44. Murashima A, Watanabe N, Ozawa N et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009;68:1793-4.
45. Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 2010;49:2225-7.
46. Keeling S, Wolbink GJ. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis. J Rheumatol 2010;37:1551.
47. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008;14:3085-7.
48. Kane S, Ford J, Cohen R et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009;43:613-6.
49. Ben-Horin S, Yavzori M, Kopylov U et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011;5:555-8.
50. Steenholdt C, Al-Khalaf M, Ainsworth MA et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis 2012;6:358-61.
51. Ostensen M, Lockshin M, Doria A et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 2008;47(Suppl 3):iii28-31.
52. Pellkofer HL, Suessmair C, Schulze A et al. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 2009;15:1006-8.
53. Ng CT, O'Neil M, Walsh D et al. Successful pregnancy after rituximab in a women with recurrent in vitro fertilisation failures and anti-phospholipid antibody positive. Ir J Med Sci 2009;178:531-3.
54. Ton E, Tekstra J, Hellmann PM et al. Safety of rituximab therapy during twins' pregnancy. Rheumatology 2011;50:806-8.
55. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004;72:292-5.
56. Ojeda-Uribe M, Gilliot C, Jung G et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26:2525.
57. Ponte P, Lopes MJ. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 2010;63:355-6.
58. Rey J, Coso D, Roger V et al. Rituximab combined with chemotherapy for lymphoma during pregnancy. Leuk Res 2009;33:e8-9.
59. Gall B, Yee A, Berry B et al. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obstet Gynaecol Can 2010;32:1167-71.
60. Martinez-Martinez MU, Baranda-Candido L, Gonzalez-Amaro R et al. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatology 2013;52:405-6.
61. Alkaabi JK, Alkindi S, Riyami NA et al. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus 2012;21:1571-4.
62. Daver N, Nazha A, Kantarjian HM et al. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 2013;13:86-9.
63. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001;19:3439.
64. Friedrichs B, Tiemann M, Salwender H et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006;91:1426-7.
65. Decker M, Rothermundt C, Hollander G et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006;7:693-4.
66. Perez CA, Amin J, Aguina LM et al. Primary mediastinal large B-cell lymphoma during pregnancy. Case Rep Hematol 2012;2012:197347.